Calculator
Line separator

MEMBERS FUNDING ANNOUNCEMENTS.

2022 NIAID Omnibus Broad Agency Announcement

Issued by: National Institute of Allergy and Infectious Diseases (NIAID)
Activity code: HHS-NIH-NIAID-BAA2022-1

Open date (earliest submission): January 2022
Expiration date: March 18 - April 18 2022

Research Area 001 - Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases 

Proposals Due Date and Time - 3:00PM Eastern Time on April 18, 2022
 

Research Area 002 - Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00PM Eastern Time on April 18, 2022
 

Research Area 003 - The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential

Proposals Due Date and Time - 3:00PM Eastern Time on March 18, 2022
 

Research Area 004 - Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00PM Eastern Time on April 18, 2022

Posted: February 01, 2022

Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design

Issued by: National Institute of Allergy and Infectious Diseases (NIAID)

Release date: September 20, 2020

Expiration date: January 08, 2023

The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals.

Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.

Posted: December 17, 2020